Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Healthy Volunteers: t
View:
• Age ≥ 30 years
• AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
• Those over 18 are also eligible if they have 2 or more family members with a blood cancer
Locations
United States
Massachusetts
Dana Farber Cancer Institute
RECRUITING
Boston
Contact Information
Primary
Irene Ghobrial, MD
promisestudy@partners.org
617-632-4198
Time Frame
Start Date: 2018-10-31
Estimated Completion Date: 2033-10-31
Participants
Target number of participants: 30000
Treatments
Specimen Collection
* Samples of blood (2-4 tablespoons) from 4 tubes will be collected~* Analysis will be performed on the blood to test for multiple myeloma precursor conditions.
Authors
Related Therapeutic Areas
Sponsors
Leads: Dana-Farber Cancer Institute